Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), LENZ Therapeutics (LENZ) and Sarepta Therapeutics (SRPT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ProKidney (PROK), LENZ Therapeutics (LENZ) and Sarepta Therapeutics (SRPT).

Claim 30% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

ProKidney (PROK)

In a report released today, Anupam Rama from J.P. Morgan maintained a Hold rating on ProKidney. The company’s shares closed last Wednesday at $1.88.

According to TipRanks.com, Rama is a 5-star analyst with an average return of 21.5% and a 50.8% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Maze Therapeutics, Inc. ;'>

Currently, the analyst consensus on ProKidney is a Hold with an average price target of $7.33, implying a 296.2% upside from current levels. In a report issued on March 18, Morgan Stanley also maintained a Hold rating on the stock with a $3.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

LENZ Therapeutics (LENZ)

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on LENZ Therapeutics today and set a price target of $56.00. The company’s shares closed last Wednesday at $9.04.

According to TipRanks.com, Caufield is a 5-star analyst with an average return of 17.5% and a 44.8% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., 4D Molecular Therapeutics, and Phathom Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for LENZ Therapeutics with a $44.68 average price target, representing a 386.2% upside. In a report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $29.00 price target.

Sarepta Therapeutics (SRPT)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Sarepta Therapeutics today and set a price target of $31.00. The company’s shares closed last Wednesday at $22.30.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -0.6% and a 36.0% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Cartesian Therapeutics, and ACADIA Pharmaceuticals. ;'>

Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $20.06, representing a 1.5% upside. In a report issued on March 16, Wedbush also assigned a Buy rating to the stock with a $29.00 price target.

Read More on PROK:

Disclaimer & DisclosureReport an Issue

• Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
• ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
• ProKidney reports Q4 EPS (52c), consensus (15c)
• Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
• ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating